CNS
![](https://www.wcgclinical.com/wp-content/uploads/2022/03/on-the-future-of-schizophrenia-trials-part-2-of-wcg-s-transforming-cns-trials-series.png)
On the Future of Schizophrenia Trials: Part 2 of WCG’s Transforming CNS Trials Series
Podcasts![](https://www.wcgclinical.com/wp-content/uploads/2022/03/on-the-future-of-psychiatric-disorders-transforming-cns-trials.png)
On the Future of Psychiatric Disorders: Part 1 of WCG’s Transforming CNS Trials Series
Podcasts![](https://www.wcgclinical.com/wp-content/uploads/2023/05/WCG-generic-visual-concepts-06.jpg)
Clinical Endpoints
How a Top 25 Pharma Company Reduced the Placebo Response for their Phase II Study
Case Studies![](https://www.wcgclinical.com/wp-content/uploads/2022/06/Thumb_Improving-Data-Quality-for-a-Critical-Multiple-Sclerosis-Endpoint.png)
Clinical Endpoints
Improving Data Quality for a Critical Multiple Sclerosis Endpoint
Blog Posts![](https://www.wcgclinical.com/wp-content/uploads/2023/05/WCG-generic-visual-concepts-03.jpg)
Clinical Endpoints
Placebo Response Reduction Training Increases Assay Sensitivity in Clinical Trials on Migraine Treatment
Research![](https://www.wcgclinical.com/wp-content/uploads/2020/07/w-320-4.jpg)
WCG’s Placebo Response Reduction Training Poster
Research![](https://www.wcgclinical.com/wp-content/uploads/2020/07/itemeditorimage_5f109f472e55e.png)
Clinical Trial Safety
Submitting Deviations from a Sponsor’s Adverse Event Reporting Requirements to the IRB
Blog Posts![](https://www.wcgclinical.com/wp-content/uploads/2022/03/informed-consent-an-irb-perspective-on-navigating-the-new-normal.jpeg)
COVID-19
Informed Consent: An IRB Perspective on Navigating the New Normal
Blog Posts![](https://www.wcgclinical.com/wp-content/uploads/2020/06/shutterstock_1914952930-scaled.jpg)
Series: Ask the IRB & IBC Experts
What documentation is needed to prove a parent’s legal authority to consent for a child’s participation in research?
Blog Posts![](https://www.wcgclinical.com/wp-content/uploads/2020/06/shutterstock_571667590-scaled.jpg)
Clinical Endpoints